Patoulias, D., & Kalogirou, M. (2018). Empagliflozin promises to bridge the gap between non-alcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease. Prz Gastroenterol.
Citação norma ChicagoPatoulias, Dimitrios, and Maria Kalogirou. "Empagliflozin Promises to Bridge the Gap between Non-alcoholic Fatty Liver Disease, Type 2 Diabetes, and Cardiovascular Disease." Prz Gastroenterol 2018.
Citação norma MLAPatoulias, Dimitrios, and Maria Kalogirou. "Empagliflozin Promises to Bridge the Gap between Non-alcoholic Fatty Liver Disease, Type 2 Diabetes, and Cardiovascular Disease." Prz Gastroenterol 2018.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.